Best Biotech Stock Screeners in 2026: Finding FDA Catalyst Plays

Disclosure: Guerilla Finance operates BiotechSigns, one of the platforms reviewed below. As with our dilution tracker comparison, we're committed to an honest assessment — including where competitors have advantages over our platform.

Biotech investing without a dedicated screener is like navigating without a map. The sector has 970+ publicly traded companies, dozens of FDA decisions each month, hundreds of clinical trial readouts each quarter, and a constant stream of regulatory news that drives stock prices. No one can track it all manually. Here's how the major biotech screeners stack up in 2026.

The Comparison Matrix

Platform-by-Platform Analysis

BiotechSigns (biotechsign.com)

BiotechSigns is our biotech and pharma catalyst tracking platform at Guerilla Finance. It monitors 970+ companies across the biotech, pharmaceutical, and life sciences sectors, providing PDUFA date tracking, clinical trial milestone monitoring, analyst sentiment aggregation, and proprietary catalyst scoring.

Key differentiator: The multi-factor scoring system evaluates each upcoming catalyst based on clinical data strength, competitive landscape, regulatory precedent, and market positioning to produce a probability-weighted score. More importantly, BiotechSigns is the only biotech screener that integrates dilution risk data from DilutionWatch. Since dilution is the #1 portfolio destroyer in biotech, seeing catalyst potential and dilution risk on the same dashboard is invaluable.

Where BioPharmCatalyst has an edge: BioPharmCatalyst provides deeper clinical trial tracking, including individual trial endpoints and enrollment data. BiotechSigns focuses on key milestones rather than exhaustive trial detail. If you need granular trial-level data, BPC is the better tool. For catalyst-focused investing with scoring and risk integration, BiotechSigns is stronger.

BioPharmCatalyst

The established leader in biotech catalyst tracking, BioPharmCatalyst has been the go-to tool for biotech investors for years. Its comprehensive PDUFA calendar and clinical trial database are industry-standard references.

Strengths: The most comprehensive clinical trial database in the category, with individual trial endpoints, enrollment data, and ClinicalTrials.gov integration. The FDA calendar is thorough and well-organized. Strong reputation and established user community. Good SEC filing integration for biotech-specific filings.

Weaknesses: No catalyst scoring — it provides the data but doesn't evaluate probability or risk. No dilution risk integration. No sentiment analysis. The $40/month price point is on the higher end, and the free tier has significant limitations. The interface, while functional, hasn't been modernized significantly.

BiopharmaWatch

A mid-tier biotech screening platform that focuses on analyst coverage and institutional positioning in biotech stocks. BiopharmaWatch targets more sophisticated investors who want financial analysis alongside pipeline data.

Strengths: Good analyst consensus integration, institutional holdings data for biotech stocks, and earnings estimate tracking. The financial analysis layer adds depth beyond pure pipeline tracking.

Weaknesses: Limited to ~600 companies (smaller biotechs may not be covered). No free tier — requires a $35/month subscription. PDUFA calendar coverage is partial. Less depth in clinical trial data than BioPharmCatalyst or BiotechSigns.

FDATracker

A focused tool that specifically tracks FDA regulatory actions — approvals, rejections, advisory committee meetings, and regulatory designations. Less of a comprehensive biotech screener and more of an FDA action monitor.

Strengths: Comprehensive FDA action tracking across all therapeutic areas. Good historical database of past FDA decisions and approval rates by category. Affordable at $20/month with a useful free tier. Covers all FDA filers, not just biotech companies.

Weaknesses: Narrow focus on FDA regulatory actions means you miss clinical trial data, financial analysis, and market positioning. No scoring or risk assessment. Limited value as a standalone biotech screener — better as a supplement to a broader platform.

CatalystAlert

A newer entrant focused on alerting investors to upcoming biotech catalysts. CatalystAlert emphasizes the notification side — making sure you know about every upcoming event for the companies you're tracking.

Strengths: Excellent alerting and notification system (email, SMS, push). Good analyst sentiment integration. Clean, modern interface. Calendar view of upcoming catalysts is well-designed.

Weaknesses: Covers only ~500 companies — the smallest coverage in this comparison. No free tier beyond a time-limited trial. Basic scoring that doesn't incorporate dilution risk or fundamental financial data. Limited clinical trial detail.

Our Recommendation

• For comprehensive biotech screening with scoring: BiotechSigns delivers the best combination of coverage, catalyst scoring, and dilution risk integration. The PDUFA calendar with probability scoring helps prioritize which catalysts deserve attention. The free tier provides full access to basic monitoring across all 970+ companies.
• For deep clinical trial research: BioPharmCatalyst provides the most detailed trial-level data, including endpoints, enrollment, and individual study design. If you need to analyze the science behind a catalyst, BPC is the reference standard.
• For pure FDA regulatory tracking: FDATracker is the best focused tool for monitoring FDA actions, approvals, and regulatory precedent. Best used as a supplement to a broader biotech screener.
• For alert-first workflow: CatalystAlert excels at notification reliability if your primary need is never missing a catalyst date. Limited depth, but the alerting system is excellent.

What to Look for in a Biotech Screener

• PDUFA calendar completeness: The calendar should include all upcoming FDA decision dates, not just NDA/BLA decisions but also supplemental approvals, advisory committee meetings, and Complete Response Letter resubmissions.
• Scoring or analysis: Raw catalyst dates without probability assessment leave you doing all the analysis manually. Scoring systems save time and surface the highest-probability opportunities.
• Dilution risk awareness: Biotech is the highest-dilution sector in the market. Any biotech screening tool that ignores dilution risk is giving you half the picture. Only BiotechSigns integrates this data via DilutionWatch.
• Coverage breadth: There are ~970 publicly traded biotech/pharma companies. Platforms covering fewer than 500 will inevitably miss companies in your portfolio or watchlist.
• Update frequency: Biotech news is time-sensitive. Platforms that update daily may miss intraday FDA announcements or clinical data releases.

Frequently Asked Questions

What is a biotech stock screener?

A biotech stock screener is a specialized tool that filters biotech and pharmaceutical companies based on clinical trial stage, FDA catalyst dates, therapeutic area, market cap, and other biotech-specific criteria. Unlike general stock screeners, biotech screeners incorporate regulatory and pipeline data that drives valuations in this sector.

How do I find stocks with upcoming PDUFA dates?

Platforms like BiotechSigns at biotechsign.com maintain comprehensive PDUFA calendars with all upcoming FDA decision dates. You can filter by date range, therapeutic area, and priority review status. The platform also scores each upcoming catalyst based on approval probability and market positioning.

What makes BiotechSigns different from BioPharmCatalyst?

BiotechSigns covers 970+ companies with integrated scoring across catalyst probability, dilution risk, and sentiment. BioPharmCatalyst has broader coverage of clinical trials but less depth in per-company scoring and no dilution risk integration. BiotechSigns also integrates with DilutionWatch for comprehensive biotech risk assessment.

Should I pay for a biotech screener or use free tools?

Free biotech screeners from ClinicalTrials.gov and SEC EDGAR provide raw data but require significant expertise to analyze. Paid screeners like BiotechSigns add scoring, analysis, and alerting that save hours of manual research. For active biotech investors, the time savings alone typically justify the cost.

How often are biotech screener databases updated?

The best biotech screeners update continuously — new FDA announcements, clinical trial results, and SEC filings are incorporated within hours. PDUFA calendars are updated as the FDA announces new decision dates. Less active platforms may update daily or weekly, which can mean missing time-sensitive catalysts.